JASPER THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
JASPER THERAPEUTICS, INC. (JSPR) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $9.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2025-02-28
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2023-12-31 was $1.00K.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2023-09-30 was $1.00K.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2023-06-30 was $1.00K.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2023-03-31 was $6.00K.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2023 was $9.00K, a 10.00% decline from fiscal 2022.
- JASPER THERAPEUTICS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2022 was $10.00K.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.00K derived: sum of 2 quarters · filed 2025-02-28 | $3.00K derived: sum of 3 quarters · filed 2025-02-28 | $9.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.00K 10-Q · filed 2024-11-07 | $2.00K derived: sum of 2 quarters · filed 2024-11-07 | $8.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.00K 10-Q · filed 2024-08-13 | $7.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $6.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $10.00K 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |